Renvela Tablet 800 mg

Uses

Renvela Tablet 800 mg is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis. Renvela Tablet 800 mg is also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus 1.78 ... Read more

Dosage

Renvela Tablet 800 mg dosage

Starting dose: The recommended starting dose of Renvela Tablet 800 mg is 2.4 g (Three Sevelamer 800 mg tablets or Three Sevelamer 800 mg sachets of powder for oral suspension) or 4.8 g (Six Sevelamer 800 mg tablets or Six Sevelamer 800 mg sachets of powder for oral suspension) per day based on clinical needs and serum phosphorus level. Renvela Tablet 800 mg tablet or suspension must be taken three times per day with meals. For patients previously on phosphate binders (Sevelamer Hydrochloride or calcium based), Renvela Tablet 800 mg should be given on a gram for gram basis with monitoring of serum phosphorus levels to ensure optimal daily doses. Titration and Maintenance: Serum phosphorus levels must be monitored and the dose of Renvela Tablet 800 mg titrated every 2-4 weeks until an acceptable serum phosphorus level is reached, with regular monitoring thereafter. Patients taking Renvela Tablet 800 mg should adhere to their prescribed diets. In clinical practice, treatment will be continuous based on the need to control serum phosphorus levels and the daily dose is expected to be an average of approximately 6 g per day. Paediatric population: The safety and efficacy of Renvela Tablet 800 mg has not been established in children below the age of 18 years. Renvela Tablet 800 mg is not recommended in children below the age of 18 years. Method of administration for Renvela Tablet 800 mg tablet: Tablets should be swallowed intact and should not be crushed, chewed, or broken into pieces prior to administration. Method of administration for Renvela Tablet 800 mg powder for oral suspension: Each sachet of 800 mg of powder is to be dispersed in 30 ml or 6 teaspoons of water prior to administration. The suspension should be ingested within 30 minutes after being prepared.

Interaction

Drug interactions: Interaction studies have not been conducted in patients on dialysis. In interaction studies in healthy volunteers, Sevelamer Hydrochloride, which contains the same active moiety as Renvela Tablet 800 mg, decreased the bioavailability of ciprofloxacin by approximately 50% when co-administered with Sevelamer Hydrochloride in a single dose study. Consequently, Renvela Tablet 800 mg should not be taken simultaneously with ciprofloxacin. Reduced levels of ciclosporin, mycophenolate mofetil and tacrolimus have been reported in transplant patients when co-administered with Sevelamer Hydrochloride without any clinical consequences (i.e graft rejection). The possibility of an interaction cannot be excluded and a close monitoring of blood concentrations of ciclosporin, mycophenolate mofetil and tacrolimus should be considered during the use of combination and after its withdrawal. Very rare cases of hypothyroidism have been reported in patients co-administered Sevelamer Hydrochloride, which contains the same active moiety as Renvela Tablet 800 mg, and levothyroxine. Closer monitoring of thyroid stimulating hormone (TSH) levels is therefore recommended in patients receiving Renvela Tablet 800 mg and levothyroxine. Patients taking anti-arrhythmic medicinal products for the control of arrhythmias and anti-seizure medicinal products for the control of seizure disorders were excluded from clinical trials. Caution should be exercised when prescribing Renvela Tablet 800 mg to patients also taking these medicinal products. In interaction studies in healthy volunteers, Sevelamer Hydrochloride, which contains the same active moiety as Renvela Tablet 800 mg, had no effect on the bioavailability of digoxin, warfarin, enalapril or metoprolol. Renvela Tablet 800 mg is not absorbed and may affect the bioavailability of other medicinal products. When administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after Renvela Tablet 800 mg, or the physician should consider monitoring blood levels.

Pregnancy & Breastfeeding use

Sevelamer carbonate is not absorbed systemically following oral administration and maternal use is not expected to result in fetal exposure to the drug. Clinical Considerations Sevelamer carbonate may decrease serum levels of fat soluble vitamins and folic acid in pregnant women.Sevelamer carbonate is not absorbed systemically by the mother following oral administration, and breastfeeding is not expected to result in exposure of the child to Sevelamer carbonate. Clinical Considerations Sevelamer carbonate may decrease serum levels of fat soluble vitamins and folic acid in pregnant women.

Contraindication

Renvela Tablet 800 mg is contraindicated in patients with bowel obstruction. Renvela Tablet 800 mg is contraindicated in patients with known hypersensitivity to sevelamer carbonate, sevelamer hydrochloride, or to any of the excipients.

Special Warning

Pediatric Use: The safety and efficacy of Renvela Tablet 800 mg in lowering serum phosphorus levels was studied in patients 6 years of age and older with CKD. In this study, Renvela Tablet 800 mg was apparently less effective in children with a low baseline serum phosphorus, which described children < 13 years of age and children not on dialysis. Given its mechanism of action, Renvela Tablet 800 mg is expected to be effective in lowering serum phosphorus levels in pediatric patients with CKD. Most adverse events that were reported as related, or possibly related, to sevelamer carbonate were gastrointestinal in nature. No new risks or safety signals were identified with the use of sevelamer carbonate in the trial. Renvela Tablet 800 mg has not been studied in pediatric patients below 6 years of age.Geriatric Use: Clinical studies of Renvela Tablet 800 mg did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range.

Acute Overdose

In CKD patients on dialysis, the maximum dose studied was 14 grams of sevelamer carbonate and 13 grams of sevelamer hydrochloride. There are no reports of overdosage with sevelamer carbonate or sevelamer hydrochloride in patients. Since sevelamer is not absorbed, the risk of systemic toxicity is low.

Storage Condition

Store in a cool and dry place, protected from light.

Innovators Monograph

You find simplified version here Renvela Tablet 800 mg